Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00968253
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00958256
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00941928
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00936936
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT00924287
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00878254
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00857389
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplant in Devic's Disease
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 13
- Registration Number
- NCT00787722
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Chemically Assisted Capsulectomy-A New Clinical Approach
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 20
- Registration Number
- NCT00758667
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
- Conditions
- Interventions
- Drug: cisplatinDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: leucovorin calciumDrug: methotrexateDrug: zoledronic acidProcedure: adjuvant therapyProcedure: neoadjuvant therapyProcedure: therapeutic conventional surgeryBiological: filgrastimDrug: Mesna
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 24
- Registration Number
- NCT00742924
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.